Skip to content

Biostax Corp.: 10-K filed 2023-04-10

What Biostax Corp. reported in its annual report filed 2023-04-10 (fiscal FY 2022): 27 published measures, 53 facts as tagged in accession 0001493152-23-011692.

This filing

Form
10-K (annual report)
Filed
2023-04-10
Fiscal period
fiscal FY 2022
Accession
0001493152-23-011692 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Biostax Corp. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2022-12-31963,719USD
At 2021-12-313,138,885USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2022-12-313,477,173USD
At 2021-12-3111,087,141USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2022-12-31-2,513,454USD
At 2021-12-31-7,948,256USD
At 2020-12-31-11,666,981USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2022-12-31150,491USD
At 2021-12-31493,885USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2022-01-01 to 2022-12-31-3,536,076USD365
2021-01-01 to 2021-12-313,586,034USD365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2022-01-01 to 2022-12-31-581,821USD365
2021-01-01 to 2021-12-31-231,717USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2022-01-01 to 2022-12-31738,427USD365
2021-01-01 to 2021-12-31715,631USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2022-01-01 to 2022-12-31-500,000USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2022-12-31-382,968,494USD
At 2021-12-31-379,432,418USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2022-01-01 to 2022-12-3136,290,359shares365
2021-01-01 to 2021-12-31482,826shares365

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2022-01-01 to 2022-12-3136,290,359shares365
2021-01-01 to 2021-12-319,394,164shares365

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2022-01-01 to 2022-12-31-0.1USD/shares365
2021-01-01 to 2021-12-317.43USD/shares365

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2022-01-01 to 2022-12-31-0.1USD/shares365
2021-01-01 to 2021-12-310.38USD/shares365

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2022-01-01 to 2022-12-310USD365
2021-01-01 to 2021-12-310USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2022-01-01 to 2022-12-31-1,163,493USD365
2021-01-01 to 2021-12-31-738,169USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2022-12-31150,491USD
At 2021-12-313,138,885USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2022-01-01 to 2022-12-31120,403USD365
2021-01-01 to 2021-12-31210,919USD365

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2022-12-313,477,173USD
At 2021-12-3111,087,141USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2022-12-311,300,366USD
At 2021-12-312,184,848USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2022-01-01 to 2022-12-311,163,493USD365
2021-01-01 to 2021-12-31738,169USD365

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2022-01-01 to 2022-12-311,149,257USD365
2021-01-01 to 2021-12-31585,502USD365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2022-01-01 to 2022-12-3114,236USD365
2021-01-01 to 2021-12-31152,667USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2022-12-3183,045,857shares
At 2021-12-31483,714shares

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2022-12-31136,057USD
At 2021-12-31239,558USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2022-01-01 to 2022-12-31-3,536,076USD365

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2022-01-01 to 2022-12-31-2,372,583USD365
2021-01-01 to 2021-12-314,324,203USD365

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2022-01-01 to 2022-12-31388,539USD365
2021-01-01 to 2021-12-31103,752USD365

Inspect the source

Entity
Biostax Corp. / CIK 0001559356
Captured
SEC response SHA-256
ecd2fd604c2830f9a246acadb5d36a2305a32fce23854ff1bf58e29fa3567754

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001559356.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))